Disc Medicine appoints Rahul Kaushik as chief technology officer [Seeking Alpha]
Disc Medicine, Inc. (IRON)
Company Research
Source: Seeking Alpha
More on Disc Medicine Disc Medicine: Achieving Functional Endpoint More Important Seeking Alpha's Quant Rating on Disc Medicine Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.MarketBeat
- Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week [Yahoo! Finance]Yahoo! Finance
- Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney WeekGlobeNewswire
- Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical OfficerGlobeNewswire
- Disc Medicine, Inc. (NASDAQ: IRON) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $89.00 price target on the stock.MarketBeat
IRON
Earnings
- 8/8/24 - Beat
IRON
Sec Filings
- 10/25/24 - Form 8-K
- 10/24/24 - Form SC
- 10/3/24 - Form 4
- IRON's page on the SEC website